In this issue:
Comparative efficacy of biologics for psoriasis with nail involvement
Bimekizumab in psoriasis
Dupilumab in moderate-to-severe atopic dermatitis
Dupilumab and risk of cutaneous T cell lymphoma
Dupilumab for atopic dermatitis in patients with malignancy and other comorbidities
Omalizumab for chronic urticaria during pregnancy
Small-molecule inhibitors and biologics for palmoplantar psoriasis and pustulosis
Adalimumab + clindamycin + rifampicin in hidradenitis suppurativa
Live attenuated vaccine administration in dupilumab-treated children
Predictive factors of dupilumab response in moderate-to-severe atopic dermatitis
Please login below to download this issue (PDF)